Compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancer
First Claim
Patent Images
1. A method of treating a MYC-associated cancer in a subject in need thereof, the method comprising:
- selecting a subject that overexpresses MYC; and
administering to the subject a pharmaceutical composition comprising a nucleic acid sequence having at least 80% complementarity to a micro RNA (miR) Responsive Element (MRE) sequence set forth as SEQ ID NO;
1, thereby treating cancer in the subject, wherein the MYC-associated cancer is further characterized by downregulation of hsa-miR-330-5p.
2 Assignments
0 Petitions
Accused Products
Abstract
Novel mIR-330 agents and their methods of use are provided. Methods of treating MYC-associated cancers are provided.
-
Citations
13 Claims
-
1. A method of treating a MYC-associated cancer in a subject in need thereof, the method comprising:
-
selecting a subject that overexpresses MYC; and administering to the subject a pharmaceutical composition comprising a nucleic acid sequence having at least 80% complementarity to a micro RNA (miR) Responsive Element (MRE) sequence set forth as SEQ ID NO;
1, thereby treating cancer in the subject, wherein the MYC-associated cancer is further characterized by downregulation of hsa-miR-330-5p. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
-
12. A method of targeting MYC overexpression in a cancer cell characterized by overexpression of MYC, comprising contacting the cell with a nucleic acid sequence having at least 80% complementarity to an MRE sequence set forth as SEQ ID NO:
- 1 to inhibit translation of the MYC mRNA, wherein the cancer cell is further characterized by downregulation of hsa-miR-330-5p.
- View Dependent Claims (13)
Specification